Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Non-current Liabilities
All obligations due after more than one year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 110528.4% from a year ago
Total non-current liabilities stood at $350.69M at the end of Q1 FY2026, up 110528.4% from a year earlier and up 344.8% from the prior quarter. Over 3 fiscal years it compounded at -31.1% a year.
Context
- Total non-current liabilities amounted to 46.9% of total assets at the end of Q1 FY2026, up 46.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +110528.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $350.69M+344.8% QoQ
- Last fiscal yearDec 2025
- $78.85M+36068.3% YoY
- Year agoMar 2025
- $317K+110528.4% since
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 78.85M USD
- Year-over-year change
- +36068.3%
- 3-year CAGR
- -31.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78.85M | +36068.3% |
| FY2024 | 2024-12-31 | 218K | -99.9% |
| FY2023 | 2023-12-31 | 270.64M | +12.3% |
| FY2022 | 2022-12-31 | 240.9M | — |
Total Non-current Liabilities vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total non-current liabilities of $350.69M is the highest of the 8 companies compared; the peer median is $390K.
- Its year-over-year change of +110528.4% is the highest of 6, against a peer median of -14.8%.
- Total non-current liabilities amounts to 46.9% of total assets for ZBIO, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $350.69M | +110528.4% | -31.1% | 46.9% | |
| Mar 2026 | $27.7M | -14.8% | -6.4% | 13.9% | |
| Mar 2026 | $22.42M | -12.7% | -9.6% | 8.5% | |
| Mar 2026 | $6.69M | -90.2% | -60.3% | 10.5% | |
UPBUpstream Bio, Inc. | Mar 2026 | $390K | -60.7% | -83.4% | 0.1% |
| Dec 2025 | $234K | — | -1.3% | 2.0% | |
| Sep 2026 | $0 | — | +127.4% | 0.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | +100.0% | — | 0.0% |
| Peer median (excluding ZBIO) | $390K | -14.8% | -8.0% | 2.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.